Xenofon Baraliakos1, Andrew S Koenig2, Heather Jones2, Annette Szumski2, David Collier2, Eustratios Bananis2. 1. From the Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany; Department of Specialty Care, Pfizer Inc., Collegeville, Pennsylvania; Inflammation Therapeutic Area, Amgen Inc., Thousand Oaks, California, USA.X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum; A.S. Koenig, DO; H. Jones, RN; A. Szumski, MS, Department of Specialty Care, Pfizer Inc.; D. Collier, MD, PhD, Inflammation Therapeutic Area, Amgen Inc.; E. Bananis, PhD, Department of Specialty Care, Pfizer Inc. baraliakos@me.com. 2. From the Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany; Department of Specialty Care, Pfizer Inc., Collegeville, Pennsylvania; Inflammation Therapeutic Area, Amgen Inc., Thousand Oaks, California, USA.X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum; A.S. Koenig, DO; H. Jones, RN; A. Szumski, MS, Department of Specialty Care, Pfizer Inc.; D. Collier, MD, PhD, Inflammation Therapeutic Area, Amgen Inc.; E. Bananis, PhD, Department of Specialty Care, Pfizer Inc.
Abstract
OBJECTIVE: Investigate the role and relation of disease duration of different factors for achieving clinical remission with anti-tumor necrosis factor (TNF) treatment in patients with active ankylosing spondylitis (AS). METHODS: Data pooled from 4 large (n = 1281) clinical trials were used to compare disease duration subgroups for placebo or sulfasalazine (SSZ) versus etanercept (ETN), which, in turn, were analyzed by age of diagnosis ≤ 40 versus > 40 years, HLA-B27 status, and baseline C-reactive protein (CRP) ≤ upper limit of normal (ULN) versus > ULN using chi-square tests, and ANCOVA. The primary efficacy measure was Assessments of SpondyloArthritis international Society (ASAS) partial remission (PR) after 12 weeks of treatment. Also analyzed were Bath AS Disease Activity Index and Functional Index, AS Disease Activity Scores, and ASAS response rates. RESULTS: Overall, a larger percentage of patients achieved ASAS-PR with ETN versus SSZ or placebo. More patients with ≤ 2-year disease duration treated with ETN experienced partial remission (34%) versus longer disease duration (30%, 27%, and 22% for > 2-5, > 5-10, and > 10 yrs, respectively; all p < 0.05). In the subgroup of patients with both disease duration ≤ 2 years and aged ≤ 40 years at diagnosis, the treatment response was even more pronounced. Similar results were seen in HLA-B27-positive patients in the disease duration ≤ 2-year subgroup. Overall, patients with high CRP at baseline had better treatment responses compared with patients with normal CRP. CONCLUSION: Treatment response under anti-TNF treatment with ETN at 12 weeks was greatest among patients with disease duration ≤ 2 years and even more pronounced in subgroups of patients ≤ 40 years old or HLA-B27-positive at diagnosis.
OBJECTIVE: Investigate the role and relation of disease duration of different factors for achieving clinical remission with anti-tumor necrosis factor (TNF) treatment in patients with active ankylosing spondylitis (AS). METHODS: Data pooled from 4 large (n = 1281) clinical trials were used to compare disease duration subgroups for placebo or sulfasalazine (SSZ) versus etanercept (ETN), which, in turn, were analyzed by age of diagnosis ≤ 40 versus > 40 years, HLA-B27 status, and baseline C-reactive protein (CRP) ≤ upper limit of normal (ULN) versus > ULN using chi-square tests, and ANCOVA. The primary efficacy measure was Assessments of SpondyloArthritis international Society (ASAS) partial remission (PR) after 12 weeks of treatment. Also analyzed were Bath AS Disease Activity Index and Functional Index, AS Disease Activity Scores, and ASAS response rates. RESULTS: Overall, a larger percentage of patients achieved ASAS-PR with ETN versus SSZ or placebo. More patients with ≤ 2-year disease duration treated with ETN experienced partial remission (34%) versus longer disease duration (30%, 27%, and 22% for > 2-5, > 5-10, and > 10 yrs, respectively; all p < 0.05). In the subgroup of patients with both disease duration ≤ 2 years and aged ≤ 40 years at diagnosis, the treatment response was even more pronounced. Similar results were seen in HLA-B27-positive patients in the disease duration ≤ 2-year subgroup. Overall, patients with high CRP at baseline had better treatment responses compared with patients with normal CRP. CONCLUSION: Treatment response under anti-TNF treatment with ETN at 12 weeks was greatest among patients with disease duration ≤ 2 years and even more pronounced in subgroups of patients ≤ 40 years old or HLA-B27-positive at diagnosis.
Entities:
Keywords:
ANKYLOSING SPONDYLITIS; EARLY MEDICAL INTERVENTION; ETANERCEPT; PLACEBO; SULFASALAZINE
Authors: Delamo I Bekele; Elizabeth Cheng; Andreas Reimold; Christian Geier; Kavya Ganuthula; Jessica A Walsh; Daniel O Clegg; Maureen Dubreuil; Prashant Kaushik; Bernard Ng; Elizabeth Chang; Ryan Duong; Jina Park; Gail S Kerr Journal: Rheumatol Int Date: 2021-11-01 Impact factor: 3.580
Authors: Jürgen Braun; Atul Deodhar; Robert Landewé; Xenofon Baraliakos; Corinne Miceli-Richard; Joachim Sieper; Erhard Quebe-Fehling; Ruvie Martin; Brian Porter; Kunal K Gandhi; Désirée van der Heijde Journal: RMD Open Date: 2018-11-21
Authors: Adrian Ciurea; Seraphina Kissling; Kristina Bürki; Xenofon Baraliakos; Manouk de Hooge; Monika Hebeisen; Eleftherios Papagiannoulis; Pascale Exer; René Bräm; Michael J Nissen; Burkhard Möller; Diego Kyburz; Michael Andor; Oliver Distler; Almut Scherer; Raphael Micheroli Journal: RMD Open Date: 2022-02